Effect of Vitamin D Supplementation on Fasting Glucose and Interleukin-10 (IL-10) in Arab Women With Impaired Fasting Glucose
Primary Purpose
Obesity
Status
Completed
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
Oral vitamin D 100,000 IU
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring fasting glucose, obesity, arab women, interleukin, diabetes, impaired fasting glucose (IFG)
Eligibility Criteria
Inclusion Criteria:
- Arab women, age 40-65
- No significant handicap or disabilities in ADL
- BMI > 25 kg/m2
- IFG of 100-125 mg/dl
Exclusion Criteria:
- Diabetes Mellitus
- Other medical conditions that may have an effect on IFG (cancer, chronic renal failure, inflammatory diseases etc)
- History of vascular disease
- Regular use of medications that may affect IFG (steroids, HRT, diuretics etc)
- Hypercalcemia (albumin corrected Ca >10.3 mg/dl)
- Inability to sign an informed consent due to mental or psychiatric ailment
Sites / Locations
- Clalit Health Services, Haifa and Western Galilee District
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Vitamin D
Placebo
Arm Description
Intervention arm: Oral vitamin D 100,000 IU once a month for three consecutive months.
Outcomes
Primary Outcome Measures
fasting glucose
interleukin-10 level
Secondary Outcome Measures
hs-CRP level
Full Information
NCT ID
NCT00877123
First Posted
April 6, 2009
Last Updated
November 9, 2011
Sponsor
Clalit Health Services
Collaborators
Rambam Health Care Campus
1. Study Identification
Unique Protocol Identification Number
NCT00877123
Brief Title
Effect of Vitamin D Supplementation on Fasting Glucose and Interleukin-10 (IL-10) in Arab Women With Impaired Fasting Glucose
Official Title
Prospective, Randomized, Double Blind Placebo Controled Clinical Trial to Assess the Effect of Vitamin D Supplementation on Fasting Glucose and IL-10 in Arab Women With Impaired Fasting Glucose.
Study Type
Interventional
2. Study Status
Record Verification Date
October 2009
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
October 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Clalit Health Services
Collaborators
Rambam Health Care Campus
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Obesity, and its metabolic consequences - impaired fasting glucose (IFG) and diabetes, is highly prevalent among Arab women in Israel and the Middle East. Since life style modification is difficult to achieve in this population it is important to assess whether other modifiable risk factors can be detected. There is evidence that the homeostasis of vitamin D has a significant role in the eventual development of diabetes. Previous cross sectional studies have shown that low 25 (OH) vitamin D levels are related to glucose intolerance, diabetes, insulin resistance and metabolic syndrome. The study hypothesis is that 25(OH) vitamin D deficiency is highly prevalent among Arab women with IFG and that vitamin D supplementation may improve IFG and by that reduce the risk for future overt diabetes. Additionally, obesity is associated with a low-grade inflammation of white adipose tissue (WAT) resulting from chronic activation of the innate immune system. In obesity, there is an increased production and secretion of a wide range of inflammatory molecules including interleukin-10 (IL-10), which may have systemic effects on WAT and other organs. To that end the investigators will assess the influence of vitamin D supplementation on IL-10 and hs-CRP.
Detailed Description
Eligible women will be invited by their primary care physician to participate in the study. After signing an informed consent women will be randomized to receive oral vitamin D 100,000 IU or similar placebo once a month for three consecutive months. Pertinent clinical and demographic date will be documented and relevant laboratory test will be performed by the primary care team. One month after the third dose the same data and tests will be retrieved on each woman. Compliance with the study protocol will be enhanced and confirmed by a research assistant.
Objectives:
To assess the relationship between IFG and 25(OH) vitamin D levels in overweight Arab women.
To assess whether vitamin D supplementation significantly improves IFG. To assess whether vitamin D supplementation significantly modifies IL-10 and hs-CRP.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
fasting glucose, obesity, arab women, interleukin, diabetes, impaired fasting glucose (IFG)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
74 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vitamin D
Arm Type
Experimental
Arm Description
Intervention arm: Oral vitamin D 100,000 IU once a month for three consecutive months.
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Oral vitamin D 100,000 IU
Intervention Description
Oral vitamin D 100,000 IU once a month for three consecutive months.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
similar placebo once a month for three consecutive months
Primary Outcome Measure Information:
Title
fasting glucose
Time Frame
4 months
Title
interleukin-10 level
Time Frame
4 months
Secondary Outcome Measure Information:
Title
hs-CRP level
Time Frame
4 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Arab women, age 40-65
No significant handicap or disabilities in ADL
BMI > 25 kg/m2
IFG of 100-125 mg/dl
Exclusion Criteria:
Diabetes Mellitus
Other medical conditions that may have an effect on IFG (cancer, chronic renal failure, inflammatory diseases etc)
History of vascular disease
Regular use of medications that may affect IFG (steroids, HRT, diuretics etc)
Hypercalcemia (albumin corrected Ca >10.3 mg/dl)
Inability to sign an informed consent due to mental or psychiatric ailment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Naim Shehadeh, MD
Organizational Affiliation
Faculty of Medicine, Technion, Haifa,
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Uzi Milman, MD
Organizational Affiliation
Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District and the Department of Family Medicine, Faculty of Medicine, Technion- Israel Institute of Technology, HAIFA, ISRAEL.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sophia Ish-Shalom, MD
Organizational Affiliation
Faculty of Medicine, Technion, Haifa,
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gila Rosen, PhD
Organizational Affiliation
Rambam Health Care Campus
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mira Barak,, PhD
Organizational Affiliation
Clalit Health Services, Haifa and Western Galilee District
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clalit Health Services, Haifa and Western Galilee District
City
Haifa
Country
Israel
12. IPD Sharing Statement
Learn more about this trial
Effect of Vitamin D Supplementation on Fasting Glucose and Interleukin-10 (IL-10) in Arab Women With Impaired Fasting Glucose
We'll reach out to this number within 24 hrs